Journal
FRONTIERS IN PHARMACOLOGY
Volume 3, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2012.00195
Keywords
schizophrenia; dopamine hypothesis; glutamate hypothesis; NMDA receptor
Categories
Funding
- Astra Zeneca
- Biomarin
- Dainippon Sumitomo/Sepracor/Sunovion
- Eli Lilly
- Forest
- Genomind
- Merck/Schering Plough
- PamLabs
- Pfizer
- PGxHealth
- Servier
- Shire
- Torrent
- Trovis
Ask authors/readers for more resources
The Dopamine Hypothesis of Schizophrenia is actively being challenged by the NMDA Receptor Hypofunctioning Hypothesis of Schizophrenia. The latter hypothesis may actually be the starting point in neuronal pathways that ultimately modifies dopamine pathways involved in generating both positive and negative symptoms of schizophrenia postulated by the former hypothesis. The authors suggest that even this latter, NMDA receptor-based, hypothesis is likely too narrow and offer a review of typical glutamate and dopamine-based neurocircuitry, propose genetic vulnerabilities impacting glutamate neurocircuitry, and provide a broad interpretation of a possible etiology of schizophrenia. In conclusion, there is a brief review of potential schizophrenia treatments that rely on the etiologic theory provided in the body of the paper.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available